OpenLB
Open Library of Bioscience
Advanced Search
CNS drugs
Mar, 2025;39 (3): 213-241.

Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review.

Frank M C Besag, Michael J Vasey, Sulagna Roy, Samuele Cortese
Author Information
  1. Frank M C Besag: East London NHS Foundation Trust, Bedford, UK. fbesag@aol.com. ORCID
  2. Michael J Vasey: East London NHS Foundation Trust, Bedford, UK. ORCID
  3. Sulagna Roy: Faculty of Environmental and Life Sciences, Centre for Innovation in Mental Health, School of Psychology, University of Southampton, Southampton, UK. ORCID
  4. Samuele Cortese: Faculty of Environmental and Life Sciences, Centre for Innovation in Mental Health, School of Psychology, University of Southampton, Southampton, UK. ORCID
PMID: 39875750 DOI: 10.1007/s40263-024-01154-4

Abstract

BACKGROUND: Raynaud syndrome (RS) is a peripheral vasculopathy characterised be impaired acral perfusion typically manifesting as skin discolouration with pallor, cyanosis and/or erythema, and increased sensitivity to cold. RS may be primary or secondary to systemic disease, lifestyle and environmental factors or medication. RS has been reported with medication to treat ADHD, but we found no recent comprehensive overview of the literature. The aim of this review is to evaluate the evidence in the published literature for Raynaud syndrome associated with medication for ADHD.
METHODS: We systematically searched PubMed and Embase from inception to 12 June 2024 for articles published in English describing cases of RS in individuals treated with stimulant medication, atomoxetine, guanfacine or clonidine. Identified cases were assessed against the Naranjo Adverse Drug Reaction Scale criteria to determine the probability of a causal relationship with the medication.
RESULTS: The initial search identified 197 articles. A total of 61 cases were identified from 15 case reports, 5 case series, 1 retrospective case-control study, and 1 retrospective cohort study. No randomised, controlled studies were identified. Implicated medications included methylphenidate, (dex)amfetamine and, more rarely, atomoxetine. Most cases were mild and resolved within weeks of discontinuation, dose reduction or switch to an alternative medication. A few cases associated with systemic disease were reported, leading to ulceration, gangrene and the need for amputation or revascularisation in some individuals. Assessment of 28 cases using the Naranjo criteria suggested a 'possible' causative role of ADHD medication in 13 cases, a 'probable' role in 13 cases and a 'definite' role in two cases.
CONCLUSIONS: Due to the uncontrolled nature of all but one of the available studies, a causal relationship between medication for ADHD and RS could not be determined reliably. However, in view of the possibility of severe sequelae, albeit in rare cases, routine monitoring for signs of RS is recommended in individuals treated with CNS stimulants or atomoxetine, especially when initiating treatment or increasing the dose. Large database studies in which individuals act as their own controls should be conducted to clarify any association between treatment with these medications and RS, controlling for confounding factors.

References

  1. World Health Organisation (WHO). International Classification of Diseases 11th Revision (ICD-11). 2022. icd.who.int/en. Accessed 26 June 2024.
  2. Pauling JD, Hughes M, Pope JE. Raynaud���s phenomenon - an update on diagnosis, classification and management. Clin Rheumatol. 2019;38(12):3317���30. https://doi.org/10.1007/s10067-019-04745-5 . [DOI: 10.1007/s10067-019-04745-5]
  3. Gerbracht DD, Steen VD, Ziegler GL, Medsger TA Jr, Rodnan GP. Evolution of primary Raynaud���s phenomenon (Raynaud���s disease) to connective tissue disease. Arthritis Rheum. 1985;28(1):87���92. https://doi.org/10.1002/art.1780280114 . [DOI: 10.1002/art.1780280114]
  4. Block JA, Sequeira W. Raynaud���s phenomenon. The Lancet. 2001;357(9273):2042���8. https://doi.org/10.1016/S0140-6736(00)05118-7 . [DOI: 10.1016/S0140-6736(00)05118-7]
  5. Garner R, Kumari R, Lanyon P, Doherty M, Zhang W. Prevalence, risk factors and associations of primary Raynaud���s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015;5(3): e006389. https://doi.org/10.1136/bmjopen-2014-006389 . [DOI: 10.1136/bmjopen-2014-006389]
  6. Haque A, Hughes M. Raynaud���s phenomenon. Clin Med. 2020;20(6):580���7. [DOI: 10.7861/clinmed.2020-0754]
  7. Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH. Raynaud���s phenomenon: a brief review of the underlying mechanisms. Front Pharmacol. 2016. https://doi.org/10.3389/fphar.2016.00438 . [DOI: 10.3389/fphar.2016.00438]
  8. Fraenkel L, Zhang Y, Chaisson CE, Maricq HR, Evans SR, Brand F, et al. Different factors influencing the expression of Raynaud���s phenomenon in men and women. Arthritis Rheum. 1999;42(2):306���10. https://doi.org/10.1002/1529-0131(199902)42:2%3c306::AID-ANR13%3e3.0.CO;2-G . [DOI: 10.1002/1529-0131(199902)42]
  9. Stjernbrandt A, Bj��r B, Andersson M, Burstr��m L, Liljelind I, Nilsson T, et al. Neurovascular hand symptoms in relation to cold exposure in northern Sweden: a population-based study. Int Arch Occup Environ Health. 2017;90(7):587���95. https://doi.org/10.1007/s00420-017-1221-3 . [DOI: 10.1007/s00420-017-1221-3]
  10. Nilsson T, Wahlstr��m J, Burstr��m L. Hand-arm vibration and the risk of vascular and neurological diseases���a systematic review and meta-analysis. PLoS ONE. 2017;12(7): e0180795. https://doi.org/10.1371/journal.pone.0180795 . [DOI: 10.1371/journal.pone.0180795]
  11. Laplanche A, Clavel F, Contassot JC, Lanouziere C. Exposure to vinyl chloride monomer: report on a cohort study. Br J Ind Med. 1987;44(10):711���5. https://doi.org/10.1136/oem.44.10.711 . [DOI: 10.1136/oem.44.10.711]
  12. Khouri C, Blaise S, Carpentier P, Villier C, Cracowski J-L, Roustit M. Drug-induced Raynaud���s phenomenon: beyond ��-adrenoceptor blockers. Br J Clin Pharmacol. 2016;82(1):6���16. https://doi.org/10.1111/bcp.12912 . [DOI: 10.1111/bcp.12912]
  13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed, text rev.). 2022.
  14. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry. 1998;59(Suppl 7):4���16. [PMID: 9680048]
  15. Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiat. 2005;57(11):1442���51. https://doi.org/10.1016/j.biopsych.2005.04.001 . [DOI: 10.1016/j.biopsych.2005.04.001]
  16. Wender PH, Tomb DA. Attention-deficit hyperactivity disorder in adults: an overview. Attention-Deficit Hyperactivity Disorder (ADHD) in Adults. 2010;176:1-37.
  17. Agnew-Blais JC, Polanczyk GV, Danese A, Wertz J, Moffitt TE, Arseneault L. Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiat. 2016;73(7):713���20. https://doi.org/10.1001/jamapsychiatry.2016.0465 . [DOI: 10.1001/jamapsychiatry.2016.0465]
  18. Cortese S, Song M, Farhat LC, Yon DK, Lee SW, Kim MS, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. Mol Psychiatry. 2023;28(11):4823���30. https://doi.org/10.1038/s41380-023-02228-3 . [DOI: 10.1038/s41380-023-02228-3]
  19. Polanczyk G, Silva de Lima M, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942���8. https://doi.org/10.1176/ajp.2007.164.6.942 . [DOI: 10.1176/ajp.2007.164.6.942]
  20. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4):e994���1001. https://doi.org/10.1542/peds.2014-3482 . [DOI: 10.1542/peds.2014-3482]
  21. National Institute for Health and Care Excellence (NICE). NICE guideline NG87 - Attention deficit hyperactivity disorder: diagnosis and management. 2018. https://www.nice.org.uk/guidance/ng87 . Accessed 4 July 2024.
  22. Briars L, Todd T. A review of pharmacological management of attention-deficit/hyperactivity disorder. The Journal of Pediatric Pharmacology and Therapeutics. 2016;21(3):192���206. https://doi.org/10.5863/1551-6776-21.3.192 . [DOI: 10.5863/1551-6776-21.3.192]
  23. Umair HM, Sandler RD, Alunno A, Matucci-Cerinic M, Hughes M. Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud���s phenomenon: a scoping review. Semin Arthritis Rheum. 2021;51(6):1200���4. https://doi.org/10.1016/j.semarthrit.2021.09.002 . [DOI: 10.1016/j.semarthrit.2021.09.002]
  24. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239���45. https://doi.org/10.1038/clpt.1981.154 . [DOI: 10.1038/clpt.1981.154]
  25. Al Aboud A, Abrams M, Mancini AJ. Blue toes after stimulant therapy for pediatric attention deficit hyperactivity disorder. J Am Acad Dermatol. 2011;64(6):1218���9. https://doi.org/10.1016/j.jaad.2009.11.010 . [DOI: 10.1016/j.jaad.2009.11.010]
  26. Bayram ��, Herg��ner S. OROS-methylphenidate-induced Raynaud���s phenomenon: a dose-related side effect. J Child Adolesc Psychopharmacol. 2015;25(6):521. [DOI: 10.1089/cap.2015.0033]
  27. Eynalli E, Metin O, Ray PC, Tahiroglu AY, Celik GG. Methylphenidate-induced Raynaud���s phenomenon. Psychiatry Clin Psychopharmacol. 2018;28:174���5.
  28. Gaddam M, Zacharias R, He W, Oster J, Ostrow P, Schumaker G, et al. Dozing off is a problem, as is a toe falling off - methylphenidate induced Raynaud���s phenomenon. Sleep. 2022;45(SUPPL 1):A347. https://doi.org/10.1093/sleep/zsac079.796 . [DOI: 10.1093/sleep/zsac079.796]
  29. Gimarc K, Junn C. Raynaud���s phenomenon with methylphenidate treatment in a patient with TBI. Journal of Head Trauma Rehabilitation. 2022;37(6):E588. https://doi.org/10.1097/HTR.0000000000000845 . [DOI: 10.1097/HTR.0000000000000845]
  30. Gnanavel S. Lisdexamfetamine and secondary Raynaud's phenomenon. The Primary Care Companion for CNS Disorders. 2018;20(5). https://doi.org/10.4088/PCC.17l02240 .
  31. G��k��en C, Kutuk MO, Co��kun ��. Dose-dependent Raynaud���s phenomenon developing from use of atomoxetine in a girl. J Child Adolesc Psychopharmacol. 2013;23(6):428���30. https://doi.org/10.1089/cap.2012.0131 . [DOI: 10.1089/cap.2012.0131]
  32. G��lc�� ��st��n NS, karaya��murlu A. Modified-release methylphenidate-induced Raynaud���s phenomenon in an adolescent with attention deficit hyperactivity disorder. Cukurova Med J. 2022;47(3):1381���3. https://doi.org/10.17826/cumj.1121992 . [DOI: 10.17826/cumj.1121992]
  33. G��lle ZN, Ali K, Murat C. Raynaud���s phenomenon related with atomoxetine treatment in a child with autism and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2019;29(8):649���50. [DOI: 10.1089/cap.2019.0025]
  34. Gupta M. Rare Side effects of stimulants: Raynaud's phenomenon. The Primary Care Companion for CNS Disorders. 2021;23(5). https://doi.org/10.4088/PCC.20l02857 .
  35. Iglesias OM. Secondary Raynaud���s phenomenon: case report. Reactions. 2015;1582:295���319.
  36. Laboe C, Batchelder E, Vasireddy D. Persistent Raynaud���s phenomenon following methylphenidate hydrochloride use during the COVID-19 pandemic. Cureus. 2021;13(9): e17647. https://doi.org/10.7759/cureus.17647 . [DOI: 10.7759/cureus.17647]
  37. Monteerarat Y, Pariwatcharakul P. Methylphenidate-induced Raynaud phenomenon developed after increasing methylphenidate in an adult with attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2019;39(2):178���9. https://doi.org/10.1097/jcp.0000000000001007 . [DOI: 10.1097/jcp.0000000000001007]
  38. Upadhya S, Nunez SE, Muruganandam M, McElwee MK, Emil NS, Sibbitt WL Jr. Raynaud���s phenomenon secondary to central nervous system stimulants: a therapeutic role of ��-1 adrenergic blockers? Semin Arthritis Rheum. 2022. https://doi.org/10.1016/j.semarthrit.2022.152115 . [DOI: 10.1016/j.semarthrit.2022.152115]
  39. Yazici IP, Yazici KU. Atomoxetine-induced Raynaud���s phenomenon: a case report. Psychiatry Clin Psychopharmacol. 2018;28:189.
  40. Ferahkaya H, Ak��A ��F. Methylphenidate-induced Raynaud���s phenomenon in two cases with attention-deficit/hyperactivity disorder. J Contemp Med. 2021;11(3):423���4. https://doi.org/10.16899/jcm.837023 . [DOI: 10.16899/jcm.837023]
  41. Meridor K, Levy Y. Systemic sclerosis induced by CNS stimulants for ADHD: a case series and review of the literature. Autoimmun Rev. 2020;19(1): 102439. https://doi.org/10.1016/j.autrev.2019.102439 . [DOI: 10.1016/j.autrev.2019.102439]
  42. Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol. 2008;14(1):30���3. https://doi.org/10.1097/RHU.0b013e3181639aaa . [DOI: 10.1097/RHU.0b013e3181639aaa]
  43. Tan G, Mintz AJ, Mintz B, Borges JC, Hines MD, Schainfeld RM, et al. Peripheral vascular manifestation in patients receiving an amphetamine analog: a case series. Vasc Med. 2019;24(1):50���5. https://doi.org/10.1177/1358863x18790101 . [DOI: 10.1177/1358863x18790101]
  44. Yu ZJ, Parker-Kotler C, Tran K, Weller RA, Weller EB. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2010;12(2):111���5. https://doi.org/10.1007/s11920-010-0093-y . [DOI: 10.1007/s11920-010-0093-y]
  45. Coulombe J, Powell J, Hatami A, Mccuaig C, Renet S, Marcoux D. Diseases of abnormal sensitivity to cold in children on psychostimulant drugs. J Cutan Med Surg. 2015;19(2):121���4. https://doi.org/10.2310/7750.2014.14052 . [DOI: 10.2310/7750.2014.14052]
  46. Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud���s syndrome in children: a retrospective case���control study of rheumatology patients. Arthritis Rheum. 2008;58(2):563���6. https://doi.org/10.1002/art.23301 . [DOI: 10.1002/art.23301]
  47. Smith V, Ickinger C, Hysa E, Snow M, Frech T, Sulli A, et al. Nailfold capillaroscopy. Best Pract Res Clin Rheumatol. 2023;37(1): 101849. https://doi.org/10.1016/j.berh.2023.101849 . [DOI: 10.1016/j.berh.2023.101849]
  48. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev. 2007;6(8):520���3. https://doi.org/10.1016/j.autrev.2006.12.006 . [DOI: 10.1016/j.autrev.2006.12.006]
  49. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71(8):1355���60. https://doi.org/10.1136/annrheumdis-2011-200742 . [DOI: 10.1136/annrheumdis-2011-200742]
  50. Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Publications; 2014.
  51. Electronic medicines compendium (emc). Summary of product characteristics (SmPC) - methylphenidate hydrochloride - 5 mg tablets. https://www.medicines.org.uk/emc/product/8724/smpc . Accessed 11 July 2024.
  52. Electronic medicines compendium (emc). Summary of product characteristics (SmPC) - dexamfetamine sulfate - 5 mg capsules. https://www.medicines.org.uk/emc/product/11004/smpc . Accessed 11 July 2024.
  53. Electronic medicines compendium (emc). Summary of product characteristics (SmPC) - Elvanse (lisdexamfetamine) - 20 mg hard capsules. https://www.medicines.org.uk/emc/product/14091/smpc . Accessed 11 July 2024.
  54. Electronic medicines compendium (emc). Summery of product characteristics (SmPC) - atomoxetine - 10 mg capsules. https://www.medicines.org.uk/emc/product/11856/smpc . Accessed 11 July 2024.
  55. Electronic medicines compendium (emc). Summary of product characteristics (SmPC) - Clonidine - 25 ��g tablets. https://www.medicines.org.uk/emc/product/6538/smpc . Accessed 11 July 2024.
  56. Health Canada. Risk of Raynaud���s phenomenon with Intuniv XR? 2016. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-intuniv-guanfacine-hydrochloride-assessing-potential-risk.html .
  57. Graham J, Coghill D. Adverse Effects of pharmacotherapies for attention-deficit hyperactivity disorder. CNS Drugs. 2008;22(3):213���37. https://doi.org/10.2165/00023210-200822030-00003 . [DOI: 10.2165/00023210-200822030-00003]
  58. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc. 2000;75(7):711���21. https://doi.org/10.4065/75.7.711 . [DOI: 10.4065/75.7.711]
  59. Parlatini V, Bellato A, Murphy D, Cortese S. From neurons to brain networks, pharmacodynamics of stimulant medication for ADHD. Neurosci Biobehav Rev. 2024;164: 105841. https://doi.org/10.1016/j.neubiorev.2024.105841 . [DOI: 10.1016/j.neubiorev.2024.105841]
  60. Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present���a pharmacological and clinical perspective. J Psychopharmacol (Oxford, England). 2013;27(6):479���96. https://doi.org/10.1177/0269881113482532 . [DOI: 10.1177/0269881113482532]
  61. Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571���90. https://doi.org/10.2165/00003088-200544060-00002 . [DOI: 10.2165/00003088-200544060-00002]
  62. Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit - hyperactivity disorder. Pharmacotherapy J Human Pharmacol Drug Ther. 2004;24(8):1020���36. https://doi.org/10.1592/phco.24.11.1020.36146 . [DOI: 10.1592/phco.24.11.1020.36146]
  63. Etehad Tavakol M, Fatemi A, Karbalaie A, Emrani Z, Erlandsson BE. Nailfold capillaroscopy in rheumatic diseases: which parameters should be evaluated? Biomed Res Int. 2015;2015: 974530. https://doi.org/10.1155/2015/974530 . [DOI: 10.1155/2015/974530]
  64. Chojnowski MM, Felis-Giemza A, Olesi��ska M. Capillaroscopy - a role in modern rheumatology. Reumatologia. 2016;54(2):67���72. https://doi.org/10.5114/reum.2016.60215 . [DOI: 10.5114/reum.2016.60215]
  65. Medicines and Healthcare products Regulatory Agency (MHRA). Clinical Practice Research Datalink (CPRD). https://www.cprd.com/ . Accessed 31 July 2024.
  66. World Health Organisation (WHO) Uppsala Monitoring Centre. VigiBase. https://who-umc.org/vigibase/ . Accessed 31 July 2024.

MeSH Term

Humans
Raynaud Disease
Attention Deficit Disorder with Hyperactivity
Central Nervous System Stimulants
Atomoxetine Hydrochloride

Chemicals

Central Nervous System Stimulants
Atomoxetine Hydrochloride
Journal Article Systematic Review
Article has an altmetric score of 9

Word Cloud

Created with Highcharts 10.0.0casesmedicationRSADHDindividualsRaynaudatomoxetineidentifiedstudiesrolesyndromesystemicdiseasefactorsreportedliteraturepublishedassociatedarticlestreatedNaranjocriteriacausalrelationshipcase1retrospectivestudymedicationsdose13treatmentBACKGROUND:peripheralvasculopathycharacterisedimpairedacralperfusiontypicallymanifestingskindiscolourationpallorcyanosisand/orerythemaincreasedsensitivitycoldmayprimarysecondarylifestyleenvironmentaltreatfoundrecentcomprehensiveoverviewaimreviewevaluateevidenceMETHODS:systematicallysearchedPubMedEmbaseinception12June2024EnglishdescribingstimulantguanfacineclonidineIdentifiedassessedAdverseDrugReactionScaledetermineprobabilityRESULTS:initialsearch197total6115reports5seriescase-controlcohortrandomisedcontrolledImplicatedincludedmethylphenidatedexamfetaminerarelymildresolvedwithinweeksdiscontinuationreductionswitchalternativeleadingulcerationgangreneneedamputationrevascularisationAssessment28usingsuggested'possible'causative'probable''definite'twoCONCLUSIONS:DueuncontrollednatureoneavailabledeterminedreliablyHoweverviewpossibilityseveresequelaealbeitrareroutinemonitoringsignsrecommendedCNSstimulantsespeciallyinitiatingincreasingLargedatabaseactcontrolsconductedclarifyassociationcontrollingconfoundingSyndromeAssociatedMedicationAttention-Deficit/HyperactivityDisorder:SystematicReview

Similar Articles

Cited By